Race Oncology (ASX:RAC) said it will launch new clinical trials for its RC220 therapy candidate in acute myeloid leukemia and non-small cell lung cancer, according to a Monday Australian bourse filing.

The company recruited principal investigators and five major clinical sites in Sydney, Melbourne, and Brisbane for the non-small cell lung cancer clinical trial, the filing said. It also identified and contracted clinical research organizations to support the trial.

The company said it has identified a clinical pathway for the potential regulatory approval of RC220 in relapsed/refractory acute myeloid leukemia, including a bridging and dose optimization stage to establish the pharmacokinetic and pharmacodynamic equivalence of RC220 with the original RC110 formulation, as well as to identify the optimal dosage regimen required to satisfy the US Food and Drug Administration Project Optimus.

It will support a low-cost, investigator-sponsored phase 1b/2 trial to identify the optimal combination of RC220 with current standard-of-care acute myeloid leukemia treatments.

Race Oncology's shares jumped over 6% in recent trading on Monday.